



Dr méd. Anne-Laure Giraudet

Spécialiste en Médecine nucléaire et Oncologie médicale

Langues

FR,EN

Expérience professionnelle

- Depuis 2026 Médecin, centre de Médecine nucléaire, Clinique de Genolier, Suisse
- Depuis 2012 Responsable du service RLT, centre de Cancérologie Léon Bérard, Lyon, France
- 2008–2012 Médecin, service de Médecine nucléaire, Institut Curie, René Huguenin, Paris, France
- 2007–2008 Fellowship, service de médecine nucléaire, Pr Hicks, Peter McCallum Cancer Centre, Melbourne, Australie
- 2006–2007 Médecin senior, service de Médecine nucléaire, Pr Sculmberger, Institut Gustave Roussy, Villejuif, France
- 2002–2006 Assistante hospitalière universitaire, service de Médecine nucléaire, Hôpital Cochin, Paris, France
- 1997–2002 Internat, service d'Oncologie et service de Médecine nucléaire, Hôpitaux de Paris, France

Recherche

- Co-investigatrice dans 10 essais cliniques sur la *targeted radionuclide therapy* (RLT), dont 2 essais de phase précoce
- Investigatrice principale dans 4 essais cliniques sur la RLT, dont 3 essais de phase précoce
- Coordinatrice nationale dans 3 essais de phase précoce sur la RLT

Publications

***Giraudet AL**, David Kryza, Michael Hofman, Aurélie Moreau, Karim Fizazi, Aude Flechon, Rodney J Hicks, Ben Tran. **PSMA targeting in metastatic castration-resistant prostate cancer: where are we and where are we going?** Ther Adv Med Oncol. 2021 Oct 26;13:17588359211053898. doi: 10.1177/17588359211053898. eCollection 2021.

*Leboulleux S, Bournaud C, Chougnet CN, Zerdoud S, Al Ghuzlan A, Catargi B, Do Cao C, Kelly A, Barge ML, Lacroix L, Dygai I, Vera P, Rusu D, Schneegans O, Benisvy D, Klein M, Roux J, Eberle MC, Bastie D, Nascimento C, **Giraudet AL**, Le Moullec N, Bardet S, Drui D, Roudaut N, Godbert Y, Morel O, Drutel A, Lamartina L, Schvartz C, Velayoudom FL, Schlumberger MJ, Leenhardt L, Borget I. **Thyroidectomy without Radioiodine in Patients with Low-Risk Thyroid Cancer.** N Engl J Med. 2022 Mar 10;386(10):923-932. doi: 10.1056/NEJMoa2111953. PMID:35263518

*Vergnaud L, **Giraudet AL**, Moreau A, Salvadori J, Imperiale A, Baudier T, Badel JN, Sarrut D. **Patient-specific dosimetry adapted to variable number of SPECT/CT time-points per cycle for 177Lu-DOTATATE therapy.** EJNMMI Phys. 2022 May 16;9(1):37. doi: 10.1186/s40658-022-00462-2.

*Olivier P, **Giraudet AL**, Skanjeti A, Merlin C, Weinmann P, Rudolph I, Hoepping A, Gauthé M. **Phase III study of 18F-PSMA-1007 versus 18F-fluorocholine PET/CT for localization of prostate cancer biochemical recurrence: a prospective, randomized, cross-over, multicenter study.** J Nucl Med. 2022 Nov 23;jnumed.122.264743. doi:10.2967/jnumed.122.264743. Online ahead of print.

*Kryza D, Wischhusen J, Richaud M, Hervieu M, Sidi Boumedine J, Delcros JG, Besse S, Baudier T, Laval PA, Breusa S, Boutault E, Clermidy H, Rama N, Ducarouge B, Devouassoux-Shisheboran M, Chezal JM, **Giraudet AL**, Walter T, Mehlen P, Sarrut D, Gibert B. **From netrin-1-targeted SPECT/CT to internal radiotherapy for management of advanced solid tumors.** EMBO Mol Med. 2023 Apr 11;15(4):e16732. doi: 10.15252/emmm.202216732. Epub 2023 Mar 6.PMID: 36876343 10.3390/ph16070995.PMID: 37513907

*Vergnaud L, Badel JN, **Giraudet AL**, Kryza D, Mognetti T, Baudier T, Rida H, Dieudonné A, Sarrut D. **Performance study of a 360° CZT camera for monitoring Lu-PSMA treatment.** EJNMMI Phys. 2023 Sep 22;10(1):58. doi: 10.1186/s40658-023-00576-1. PMID: 37736779; PMCID: PMC10516832.177

*Sevrin F, Kolesnikov-Gauthier H, Cougnenc O, Bogart E, Schleiermacher G, Courbon F, Gambart M, **Giraudet AL**, Corradini N, Badel JN, Rault E, Oudoux A, Deley MCL, Valteau-Couanet D, Defachelles AS. **Phase II study of 131 I-metaiodobenzylguanidine with 5 days of topotecan for refractory or relapsed neuroblastoma: Results of the French study MIITOP.** Pediatr Blood Cancer. 2023 Nov;70(11):e30615. doi: 10.1002/pbc.30615. Epub 2023 Aug 13. PMID: 37574821

*Kryza D, Vinceneux A, Bidaux AS, Garin G, Tatu D, Cropet C, Badel JN, Perol D, **Giraudet AL.** **A multicentric, single arm, open-label, phase I/II study evaluating PSMA targeted radionuclide therapy in adult patients with metastatic clear cell renal cancer (PRadR).** BMC Cancer. 2024 Feb 1;24(1):163. doi:10.1186/s12885-023-11702-8. PMID: 38302933; PMCID: PMC10835868

*Flippot R, Telli T, Velez M, Fléchon A, De Vries-Brilland M, Turpin L, Bergman A, Turco F, Mahammedi H, Fendler WP, **Giraudet AL**, Josset Q, Montravers F, Vogel W, Gillessen S, Berardi Vilei S, Herrmann K, Kryza D, Paone G, Hadaschik B, Merlin C, Dufour PA, Bernard-Tessier A, Naoun N, Patrikidou A, Garcia C, Foulon S, Pagès A, Fizazi K. **Activity of Lutetium-177 Prostate-specific Membrane Antigen and Determinants of Outcomes in Patients with Metastatic Castration-resistant Prostate Cancer Previously Treated with Cabazitaxel: The PACAP Study.** Eur Urol Oncol. 2024 Apr 24:S2588-9311(24)00094-4. doi: 10.1016/j.euo.2024.03.013.

*Leboulleux S, Bournaud C, Chougnet CN, Lamartina L, Zerdoud S, Do Cao C, Catargi B, Dygai I, Kelly A, Barge ML, Vera P, Rusu D, Schneegans O, Roux J, Raymond P, Benisvy D, Eberle MC, Bidault S, Nascimento C, Bastie D, **Giraudet AL**, Bardet S, Le Moullec N, Roudaut N, Drui D, Godbert Y, Zalzali M, Drutel A, Morel O, Velayoudom FL, Al Ghuzlan A, Schlumberger M, Buffet C, Borget I. **Thyroidectomy without radioiodine in patients with low-risk thyroid cancer: 5 years of follow-up of the prospective randomised ESTIMABL2 trial.** Lancet Diabetes Endocrinol. 2025 Jan;13(1):38-46. doi: 10.1016/S2213-8587(24)00276-6. Epub 2024 Nov 22. PMID: 39586309.

*Binzaqr S, Kryza D, **Giraudet AL**, Bernhard JC, Gross-Goupil M, Yacoub M, Margue G, Hindié E, Morgat C. **Prostate-specific membrane antigen (PSMA) expression in primary and metastatic renal cell cancer (UroCCR-65 study).** EJNMMI Res. 2025 Apr 9;15(1):38. doi: 10.1186/s13550-025-01232-8. PMID: 40205264; PMCID: PMC11981970.

Accréditation

[Clinique de Genolier](#)

Spécialités

[Médecine nucléaire](#)

[Oncologie](#)

Contactez-nous

Centre de Médecine nucléaire
Clinique de Genolier
Route du Muids 3
1272 Genolier

T +41 22 366 93 15

MedecineNucleaire@genolier.net

[Téléchargez la vCard](#)